Durability of the mitroflow pericardial valve at ten years

From 1983 to 1992, 366 patients received 407 Mitroflow pericardial valves. Mean age was 62 ±14 years. Average follow-up was 72 ±28 months. Total follow-up was 1,791 patient-years. Overall survival in all patients was 77.2% ± 2.2% at 5 years and 56.2% ± 6.4% at 10 years. Freedom from structural valve deterioration was 95% ± 1.2% and 36.7% ± 8.1% at 5 and 10 years for all valves, 96.9% .3% and 39.2% ± 9.8% for aortic valve replacement, and 91.7% ± 3.2% and 36.4% ±10% for mitral valve replacement (p = not significant). The freedom from structural valve deterioration in patients older than 70 years of age was 100% and 93.9% ± 5.8% at 5 and 10 years respectively. At 10 years, linearized rate of thromboembolism was 0.73% ± 0.2% per patient-year and freedom from valve-related mortality for all valves was 88.8% ±2.8%. The best indication for the implantation of a Mitroflow valve is mitral or aortic disease in patients more than 70 years of age.